Intensive Immunochemotherapy May Yield Positive Outcomes in Burkitt Lymphoma
Researchers assessed data from Australian population-based lymphoma registries to determine the efficacy of intensive immunochemotherapy for Burkitt lymphoma.
Hematologic Cancers News
HEMATOLOGIC CANCER ADVISOR
Hematologic Cancers News
Best Practices for Diagnosing Breast Implant-Associated Anaplastic Large Cell Lymphoma
In 2016, the World Health Organization classified BIA-ALCL as a novel lymphoma.
Priority Review Granted to Tazemetostat for Follicular Lymphoma Indication
The Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for Tazverik® (tazemetostat; Epizyme) for the treatment of patients with relapsed or refractory follicular lymphoma (FL) who have received at least 2 prior lines of systemic therapy.
The Questionable Practice That Permeates Oncology Clinical Trials
Most oncology phase 1 trials use a simplistic, outdated dose-finding technique, and experts agree that change is needed.
Comparing Cost-Effectiveness of First-Line Treatment Approaches for Hodgkin Lymphoma
Of 5 treatment regimens assessed, a PET-adapted de-escalation treatment approach was found to be the most cost-effective in 87% of cases modelled.
Single-Agent Daratumumab May Delay Progression of Smoldering Multiple Myeloma
In this study, 1 of the criteria for defining intermediate- or high-risk smoldering multiple myeloma was clonal bone marrow plasma cells between 10% and less than 60%.
BEGEV Salvage Regimen Linked to High Complete Remission Rates
5-year results from that a study on BEGV have confirmed its benefits in classical Hodgkin lymphoma.
Total Therapy Approach May Improve Transplant Outcomes in Patients With Myeloma
Patients who were enrolled in clinical trials that employed a total therapy protocol had a lower early mortality rate compared with patients not on a total therapy protocol.
Integrative Oncology: Using Evidence-Informed Medicine to Improve Patient Outcomes and Quality of Life
Lifestyle-based integrative treatment approaches — deemed scientifically sound by the field’s proponents — merge conventional and complementary treatments.
Epidemiologic Evidence of an Association Between Dengue Viral Infection and Leukemia
Risk of a leukemia diagnosis was found to be highest between 3 to 6 years following manifestation of symptoms associated with dengue viral infection.
Prognostic Factors for Patients Undergoing Autologous Stem Cell Transplant for DLBCL
Researchers assessed potential differences in transplant outcomes in Japan before and after the era that introduced rituximab treatment.
Molecular Targets Identified for Rare Type of Breast Implant–Associated Lymphoma
The JAK-STAT pathway as well as epigenetics may play a role in the development of breast implant–associated anaplastic large-cell lymphoma.
Is Tisagenlecleucel for Relapsed Pediatric Acute Lymphoblastic Leukemia Cost-Effective?
Researchers assessed whether the incremental cost per quality-adjusted life-year of tisagenlecleucel matched estimated willingness-to-pay thresholds.
Brentuximab Vedotin May Improve Survival in Stage III/IV Classical Hodgkin Lymphoma
Patients who received treatment with brentuximab vedotin experienced improved progression-free survival.
Venetoclax and Obinutuzumab May Benefit CLL Patients With Complex Karyotype
Patients with CLL who have complex karyotype appear to have better clinical outcomes with venetoclax and obinutuzumab compared with chlorambucil and obinutuzumab.
Current and Prospective Treatment Options for Waldenström Macroglobulinemia
Researchers discussed diagnostic considerations, indications for therapy, and treatment options for patients with Waldenström macroglobulinemia.
Oral Oncology Parity Laws Don’t Make Medications More Affordable
Out-of-pocket spending remains high for many patients with blood cancers who are receiving tyrosine kinase inhibitors and immunomodulatory drugs.
Machine Learning Identifies Newly Diagnosed CLL Patients at Risk for Certain Outcomes
Machine learning may help identify newly diagnosed patients with CLL who are at risk for infection or treatment within 2 years of a diagnosis.
Survival Trends With Chronic Lymphocytic Leukemia Over 28 Years in the Netherlands
Relative survival rates were found to improve for all patient age groups over time, although excess mortality persisted to some degree.
Novel Heavy Metal Scoring System May Predict Survival Outcomes in Acute Myeloid Leukemia
Researchers hypothesized that imbalances of toxic and essential metals in patients with acute myeloid leukemia may be associated with poorer survival.
Want to read more?
Please login or register first to view this content.
Next post in Chronic Lymphocytic Leukemia
